TxCell SA , a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, announced that Stephane Boissel, CEO of TxCell, and other senior management will chair and participate at roundtables, present at and attend, a number of leading scientific conferences during the second quarter of 2016.

TxCell will give updates about the development of its pipeline and technology platforms, including its second platform based on CAR-Tregs, ENTrIA.

These conferences include: PEGS Summit Boston, April 25-29, Boston, United States. Arnaud Foussat, CSO of TxCell, will give a presentation entitled ‘Regulatory T Cells-Based Cellular Immunotherapy of Inflammation and Autoimmunity’ on April 26.

World Stem Cells & Regenerative Medicines Congress 2016, May 18-20, London, United Kingdom.

Stéphane Boissel, CEO of TxCell, will present TxCell’s strategy and latest developments in the ‘Biotech updates’ roundtables on May 19.

Miguel Forte, COO of TxCell, will participate in the health economics panel entitled ‘Overcoming the reimbursement hurdles in cell and gene therapies globally’ on May 18.

ISCT (International Society for Cell Therapy) 2016 Annual Meeting, May 25-28, Singapore. Two abstracts have been accepted as posters and will be presented by TxCell scientists.

Miguel Forte will co-chair a plenary session entitled ‘Opportunities and Challenges for Cell Therapy Commercialization in Asia’ on May 28.

North American Adoptive T Cell Therapy Congress, June 28-30, Boston, United States

Arnaud Foussat will chair a workshop entitled ‘T-Cell based treatment of inflammation: antigen-specific Treg cells, TCR and CAR engineered Treg cells in transplantation, autoimmunity and chronic inflammatory diseases’ on June 28.

Arnaud Foussat will also give a presentation entitled ‘Assessing Regulatory T-Cells as Therapy’ on June 30.